VSIG4 (EU-103 Biosimilar) Recombinant Monoclonal Antibody
-
貨號(hào):CSB-RA896869MB2HU
-
規(guī)格:¥83486
-
其他:
產(chǎn)品詳情
-
產(chǎn)品描述:VSIG4(EU-103 Biosimilar Antibody)重組單克隆抗體是一種用于科研領(lǐng)域的生物制劑,其研發(fā)旨在為相關(guān)研究提供高質(zhì)量的工具。該抗體針對(duì)VSIG4靶點(diǎn)設(shè)計(jì),通過重組DNA技術(shù)在實(shí)驗(yàn)室環(huán)境中制備而成,具有高度的特異性和結(jié)合活性。 在科研應(yīng)用中,VSIG4重組單克隆抗體可用于多種實(shí)驗(yàn)場(chǎng)景,包括但不限于細(xì)胞水平的蛋白表達(dá)檢測(cè)分析以及組織切片的研究等。其高純度和批次間的一致性有助于確保實(shí)驗(yàn)結(jié)果的可靠性與可重復(fù)性,為研究人員提供穩(wěn)定的實(shí)驗(yàn)條件。 該抗體的制備過程嚴(yán)格遵循生物制藥級(jí)別的質(zhì)量控制標(biāo)準(zhǔn),從基因克隆、細(xì)胞培養(yǎng)到蛋白純化均采用規(guī)范化流程,以保證最終產(chǎn)品的生物活性和結(jié)構(gòu)完整性。通過特異性識(shí)別VSIG4蛋白,該抗體能夠幫助科研人員深入探究VSIG4在免疫調(diào)節(jié)、炎癥反應(yīng)、腫瘤微環(huán)境等生理及病理過程中的作用機(jī)制。 作為科研工具,VSIG4重組單克隆抗體為免疫學(xué)、細(xì)胞生物學(xué)及相關(guān)疾病研究領(lǐng)域提供了重要支持,有助于推動(dòng)對(duì)VSIG4靶點(diǎn)功能的深入理解,為后續(xù)的基礎(chǔ)研究和藥物開發(fā)奠定實(shí)驗(yàn)基礎(chǔ)。其應(yīng)用范圍覆蓋基礎(chǔ)實(shí)驗(yàn)室研究、疾病模型構(gòu)建以及藥物靶點(diǎn)驗(yàn)證等多個(gè)科研環(huán)節(jié),是相關(guān)領(lǐng)域研究中不可或缺的實(shí)驗(yàn)試劑之一。
-
Uniprot No.:
-
基因名:
-
別名:Anti-VSIG4 antibody(Eutilex) research-grade biosimilar; Anti-VSIG4 antibody Eutilex research-grade biosimilar; EU 103 research-grade biosimilar; EU-103 research-grade biosimilar ;VSIG4 antibody; CRIg antibody; Z39IG antibody; UNQ317/PRO362 antibody; V-set and immunoglobulin domain-containing protein 4 antibody; Protein Z39Ig antibody
-
反應(yīng)種屬:Human
-
免疫原:Recombinant Human VSIG4 protein
-
免疫原種屬:Homo sapiens (Human)
-
標(biāo)記方式:Non-conjugated
-
克隆類型:Monoclonal
-
濃度:It differs from different batches. Please contact us to confirm it.
-
保存緩沖液:0.01M PBS,pH7.4
-
產(chǎn)品提供形式:Liquid
-
應(yīng)用說明:Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity?> 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method. -
儲(chǔ)存條件:Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
貨期:3-4 weeks
-
用途:It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.
相關(guān)產(chǎn)品
靶點(diǎn)詳情
-
功能:Phagocytic receptor, strong negative regulator of T-cell proliferation and IL2 production. Potent inhibitor of the alternative complement pathway convertases.
-
基因功能參考文獻(xiàn):
- Soluble VSIG4 levels are associated with the progression and recurrence of ovarian cancer, indicating that soluble VSIG4 may be used as a potential biomarker for predicting tumor prognosis. PMID: 28498255
- VSIG4 signaling provides an anti-immune evasion mechanism that prevents the outgrowth of intracellular bacteria in macrophages PMID: 27440002
- The VSIG4 upregulation by LMP1 was regulated at the transcriptional level via the NF-kB signaling axis. PMID: 28859984
- VSIG4 expression is significantly upregulated in human masticatory mucosa during wound healing PMID: 28005267
- we concluded that let-7g-5p inhibits epithelial-mesenchymal transition (EMT) consistent with reduction of glioma stem cell (GSC) phenotypes by targeting VSIG4 in glioblastoma. PMID: 27634309
- Data indicate that rotein kinase calpha (PKCalpha) plays a role in downregulating complement receptor Ig (CRIg coded by V-set and Ig domain-containing protein 4 VSIG4) expression. PMID: 25687755
- complement receptor of the immunoglobulin superfamily-L-factor H protects glomerular mesangial cells from complement-mediated injury and proliferative lesions PMID: 25114177
- we identified VSIG4 as a potential diagnostic marker of severe preeclampsia. The determination of this gene may improve the prognostic assessment of severe preeclampsia. PMID: 24349325
- Data indicate that massive V-set and Ig domain-containing 4 VSIG4(+) cell infiltration throughout the non-small-cell lung cancer samples. PMID: 24862966
- we showed that a complement receptor of the Ig superfamily (CRIg, also known as Z39Ig), a receptor for complement fragments (C3b and iC3b), was expressed on a subset of intestinal macrophages in murine and human large intestine PMID: 21768202
- These results suggest that T cells can opposite T cell hyporesponsiveness through dampening Z39Ig inhibitory signals from macrophages and thus maintain their anti-viral function in chronic hepatitis B. PMID: 20399148
- hVSIG4 recombinant adenovirus-transfected DCs suppress T cell proliferation, cytokine production and activation marker expression with PMID: 19914289
- Results report the identification and characterization of a Complement Receptor of the Immunoglobulin superfamily, CRIg, that binds complement fragments C3b and iC3b. PMID: 16530040
- These data indicate that the macrophage Z39Ig is involved in the pathogenesis of inflammatory diseases through chemokine induction, which will promote the migration of inflammatory cells into the lesion area, and MMP-9 induction. PMID: 16882875
- The specific expression of VSIG4 on resting macrophages suggests that VSIG4 may be important for the maintenance of T cell unresponsiveness in healthy tissues. PMID: 17016562
- CRIg is not only a phagocytic receptor, but also a potent inhibitor of the alternative pathway convertases PMID: 17051150
顯示更多
收起更多
-
亞細(xì)胞定位:Membrane; Single-pass type I membrane protein.
-
組織特異性:Abundantly expressed in several fetal tissues. In adult tissues, highest expression in lung and placenta. Expressed in resting macrophages.
-
數(shù)據(jù)庫(kù)鏈接:
Most popular with customers
-
YWHAB Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC, IF, FC
Species Reactivity: Human, Mouse, Rat
-
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC
Species Reactivity: Human
-
-
-
-
-
-















